Prathima Prodduturi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Prathima Prodduturi has a total of 1 co-authors. Here are the top co-authors by number of shared publications:
Philip J Bierman
University of Nebraska Medical Center, Division of Hematology and Oncology, Omaha, Ne, USA 68198–7680
1 shared publication
Latest Publications
- Open Access
- 1 January 2012
- Published by SAGE Publications in Clinical Medicine Insights: Oncology
- Vol. 6, 219-31
Current and Emerging Pharmacotherapies for Primary CNS Lymphoma
Primary central nervous system lymphoma (PCNSL) constitutes a rare group of extranodal non-Hodgkin's lymphoma (NHL) primarily of B cell origin. It occurs in both immuno-competent and immune-compromised patients. High dose methotrexate (HD-MTX) based chemotherapy is the standard therapy. Chemotherapy with whole brain radiation therapy (WBRT) improves response rates and survival compared with WBRT alone. However, due to the increased risk for neurotoxicity with WBRT, recent studies have focused on using chemotherapy alone. Methotrexate based multi-agent chemotherapy without WBRT is associated with similar treatment rates and survival compared with regimens that include WBRT although controlled trials have not been performed. Because of the low incidence of this disease, it is difficult to conduct randomized controlled trials. In this article we have discussed about the past, present and emerging treatment options in patients with PCNSL.
- 1 January 2012
- Published by SAGE Publications in Clinical Medicine Insights: Oncology
- Vol. 6, 219-31
Open AccessCurrent and Emerging Pharmacotherapies for Primary CNS Lymphoma
Primary central nervous system lymphoma (PCNSL) constitutes a rare group of extranodal non-Hodgkin's lymphoma (NHL) primarily of B cell origin. It occurs in both immuno-competent and immune-compromised patients. High dose methotrexate (HD-MTX) based chemotherapy is the standard therapy. Chemotherapy with whole brain radiation therapy (WBRT) improves response rates and survival compared with WBRT alone. However, due to the increased risk for neurotoxicity with WBRT, recent studies have focused on using chemotherapy alone. Methotrexate based multi-agent chemotherapy without WBRT is associated with similar treatment rates and survival compared with regimens that include WBRT although controlled trials have not been performed. Because of the low incidence of this disease, it is difficult to conduct randomized controlled trials. In this article we have discussed about the past, present and emerging treatment options in patients with PCNSL.